| BACKGROUND
Heart failure (HF) has emerged as a major epidemic and is a significant public health burden. It is associated with considerable morbidity and mortality. 1 There are numerous clinical parameters that predict clinical outcome. Albumin, a standard clinical parameter that is associated with multiple parameters affecting outcome including nutritional, inflammatory, and volume status of HF patients, should have a significant impact on clinical outcome in these patients. Despite this, there is limited and conflicting evidence in the literature regarding this parameter as an important predictor of outcome in chronic HF. [2] [3] [4] We hypothesized that this parameter would have a significant impact on clinical outcome in patients with chronic HF. We evaluated the impact of serum albumin levels on clinical outcome in a large real-world cohort of patients with chronic HF.
| METHODS
Clalit Health Services is the largest health maintenance organization (HMO) in Israel. It has a central computerized database in which all members have a complete digital record. The database includes demographics, comprehensive clinical data, diagnoses, and all laboratory data undertaken in a single centralized laboratory of the HMO. We identified and retrieved electronically from the computerized database all members with a diagnosis of HF as coded by the database in Jerusalem using the International Classification of Diseases, Ninth Revision (ICD-9) code 428. About 6946 patients had a diagnosis of HF. Validation of the diagnosis of HF was performed on a randomly computer-generated 5% of the diagnosed HF patients (N = 338) as previously described. 5 Clinical parameters in this group of patients were statistically comparable with the whole HF cohort. We reviewed all available data from medical records and hospital admissions. In this group, 99% fulfilled the European Society of Cardiology (ESC) criteria for the diagnosis of HF 6 based on typical symptoms, signs and structural or functional abnormalities of the heart per echocardiography.
Only 1% had equivocal clinical data for the diagnosis of HF. Natriuretic peptides are not routinely performed in Israel and
were not available for analysis. Serum albumin levels are routinely performed as part of a periodic work-up in all members of the HMO. All patients in this cohort with serum albumin levels measured within 4 months of the time the database was established were included. 3 | RESULTS
| Clinical parameters
The study cohort included 5779 HF patients. Supporting information heart disease, increased urea, low hemoglobin and sodium, nontreatment with ACE-I/ARB and thiazide, low iron and increased CRP were predictive of low serum albumin (R 2 = 0.278, P < 0.0001, Table SS1 ).
| Albumin levels and clinical outcome
The median follow-up period was 576 days. The overall mortality rate during this period was 14%. Survival rate by Kaplan-Meier analysis demonstrated that decreasing albumin levels were directly associated with reduced survival (decreasing albumin quartiles: 95.7 ± 0.6% vs 92.9 ± 0.8% vs 88.3 ± 0.8% vs 67.2 ± 1.2%, P < 0.001). Decreasing albumin levels were also directly associated with decreased event-free survival from death or cardiovascular-hospitalizations (decreasing Prior coronary bypass surgery 200 (13) 270 (16) 228 (20) 289 (21) 987 (17) <0.001
Chronic obstructive lung disease 129 (8) 193 (11) 137 (12) 125 (9) 584 (10) 0.002
Peripheral vascular disease 338 (22) 325 (19) 186 (16) 197 (14) 1046 (8) <0.001
Prior stroke/transient ischemic attack 478 (30) 385 (23) 231 (20) 245 (18) 1339 (23) <0.001
Dementia 290 (18) 166 (10) 73 (6) 68 (5) 597 ( 
for significant predictors demonstrated that decreasing albumin levels were a significant predictor of mortality (Table 2 and Figure 1A ). After adjustment for other significant predictors (see Table 2 for significant clinical predictors included), low albumin levels (<3.8 g/dL) was associated with a 5-fold increase in mortality compared to the highest albumin quartile (>4.2 g/dL), with a hazard ratio of 5.74, 95% confidence interval (CI) 4.08 to 8.07, P < 0.001. Inclusion of HF medications (Table 3 ) demonstrated a very similar result with a direct relation between reduced albumin levels and mortality. We performed a further sensitivity analysis by analyzing albumin levels as a continuous parameter using restricted cubic splines. Cox regression analysis after adjustment for significant parameters included in Table 2 demonstrated a direct inverse relationship between albumin and mortality (Figure 2A ). This analysis demonstrated that any decrease in albumin was a predictor of mortality with a continuous increase in the risk with lower albumin levels ( Figure 2A) , P < 0.0001 for the adjusted model.
Low albumin levels were also a significant predictor of the combined endpoint of death and cardiovascular hospitalization. Multivariate Cox regression analysis after adjustment for significant predictors demonstrated that decreasing albumin levels were a significant predictor of the combined endpoint (Table 3 and Figure 1B ).
After adjustment for other significant predictors, low albumin levels (<3.8 g/dL) was associated with a 2-fold increase in death and cardiovascular hospitalization compared with the highest albumin quartile (>4.2 g/dL), with a hazard ratio of 2.19, 95% CI 1.93 to 2.48, P < 0.001. Inclusion of HF medications (Table 3 ) demonstrated a very similar result, with a direct relation between reduced albumin levels and the combined endpoint of mortality and cardiovascular hospitalization Table 3 .
Subgroup analysis of patients with echocardiographic data regarding left ventricular EF (N = 1489) revealed a very similar result, with decreasing levels of albumin a significant independent predictor of death or the combined endpoint of death and cardiovascular hospitalization after adjustment for significant predictors including LV EF. This was also evident in the model that included medications. Separate analysis of patients with preserved vs reduced LV EF demonstrated that these results were equally evident in both groups. In addition, in the Cox regression models of the entire cohort, there was no significant interaction between albumin and LV EF. These results suggest that low albumin is a significant predictor of clinical outcome in HF with preserved as well as reduced LV EF. in albumin levels as a continuous parameter using restricted cubic splines was performed. Cox regression analysis after adjustment for significant parameters including baseline albumin demonstrated a direct relationship between the decrease in albumin and mortality ( Figure 2B ). This analysis demonstrated that any decrease in albumin over time was a predictor of mortality with a continuous increase in the risk with decreasing albumin levels on follow-up ( Figure 2B ), P < 0.0001 for the adjusted model.
| Changes in albumin and impact on outcome

| DISCUSSION
In this cohort of real-world HF patients, low albumin level was a significant predictor of death as well as death and cardiovascular hospitalizations. This direct inverse relationship between albumin and clinical outcome appears to be relevant across the whole spectrum of albumin levels. Moreover, the present study suggests that a decrease in albumin over time conveys additional predictive value with a significant negative impact on clinical outcome.
Albumin is a hepatic synthesized protein that is associated with numerous detrimental biological processes that are present in HF and pertain to a worse outcome. 9 Low albumin in HF patients may be due to volume overload causing hemodilution, a chronic inflammatory state, liver congestion, malnutrition and cachexia, all causing decreased synthesis of albumin, and less commonly, protein loss due to proteinuria or enteropathy. Conversely, low albumin has a negative impact on several clinical aspects of HF. Albumin has an important role in numerous physiological processes including maintaining colloid
Cox regression adjusted survival plots according to serum albumin levels. A, Decreasing albumin levels were directly associated with reduced survival, P < 0.001 for the adjusted model. B, Decreasing albumin levels were directly associated with decreased event-free survival from death or cardiovascular-hospitalizations, P < 0.001 for the adjusted model. Variables included in the adjusted model included age, gender, ischemic heart disease, diabetes, hyperlipdemia, hypertension, atrial fibrillation, log-transformed body mass index, log-transformed pulse, logtransformed serum urea levels, square root-transformed estimated glomerular filtration rate, hemoglobin, and serum sodium Data are presented as hazard ratio (95% confidence interval), P value. Parameters that were included in the multivariable analysis model were age, gender, ischemic heart disease, diabetes, hyperlipidemia, hypertension, atrial fibrillation, log-transformed body mass index, log-transformed pulse, log-transformed serum urea levels, square root-transformed estimated glomerular filtration rate, hemoglobin, and serum sodium. Parameters that were included in the multivariable and drugs analysis included the above parameters and the drug treatment with angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, beta blocker, furosemide, spironolactone, thiazide, and digoxin.
FIGURE 2
Mortality as a function of serum albumin and change in serum albumin. A, Cox regression analysis with adjusted hazard ratio for mortality (with 95% [CI]) of serum albumin as a continuous variable using restricted cubic splines with 4 knots at the 5th, 35th, 65th and 95th percentiles of serum albumin (3.1, 3.8, 4.1, 4.5 g/dL), P < 0.0001 for the adjusted model. Variables included in the model included age, gender, ischemic heart disease, diabetes, hyperlipdemia, hypertension, atrial fibrillation, log-transformed body mass index, logtransformed pulse, log-transformed serum urea levels, square roottransformed estimated glomerular filtration rate, hemoglobin, and serum sodium. B, Cox regression analysis with adjusted hazard ratio for mortality (with 95% CI) of the change in serum albumin as a continuous variable using restricted cubic splines with knots at the 5th, 35th, 65th, and 95th percentiles of serum albumin change (−0.7, −0.1, 0.1, 0.5 g/dL), P < 0.0001 for the adjusted model. Variables included in the model included age, gender, ischemic heart disease, diabetes, hyperlipdemia, hypertension, atrial fibrillation, logtransformed body mass index, log-transformed pulse, log-transformed serum urea levels, square root-transformed estimated glomerular filtration rate, hemoglobin, serum sodium, and baseline albumin measure of nutritional state. Low albumin was also associated with right HF, tricuspid regurgitation, and pulmonary hypertension. This most probably is related to the increased liver congestion seen in these patients, 20 suppressing albumin synthesis.
An interesting and important finding in the present study was that changes in albumin levels over time have prognostic implications in chronic HF. A decline in albumin levels predicted a worse clinical outcome independently of baseline albumin levels. A very similar finding was reported in the setting of chronic HF. 21 This finding is plausible biologically, as decline in albumin over time characterizes the deteriorating state of the HF patient. Acute temporal changes in albumin have been analyzed in the setting of acute HF 16, 22 and provide prognostic information. An increase in albumin levels during hospitalization predicted a better long-term outcome, while a decrease predicted a worse outcome. In the acute setting, these changes are related to the acute event severity, sequel and its progression. In the chronic setting, these changes probably reflect the progression of the chronic disease with albumin reflecting the detrimental biological processes associated with low albumin and its significance to prognosis. Limitations of this study: The present study was an observational study. Data regarding clinical parameters and drug therapy was based on a digitized database. Although this database was validated and found to be highly accurate, not all data could be verified. While we tried to adjust for clinical relevant parameters, not all clinical parameters were available and it is impossible to adjust for all variables that may affect outcome. In particular, data on functional capacity and natriuretic peptide levels were not available. In addition, the cohort was a community-based cohort and the findings may not be applicable in more advanced or hospital-based HF cohorts.
In conclusion, low serum albumin provides important information regarding several detrimental processes in HF and is a significant predictor of a worse outcome in these patients. A decline in albumin was also a predictor of reduced survival.
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